- Home
- COP vs SNY Comparison
COP vs SNY Comparison
Compare COP & SNY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- COP
- SNY
- Stock Information
- Founded
- COP 1917
- SNY 1994
- Country
- COP United States
- SNY France
- Employees
- COP N/A
- SNY N/A
- Industry
- COP Integrated oil Companies
- SNY Biotechnology: Pharmaceutical Preparations
- Sector
- COP Energy
- SNY Health Care
- Exchange
- COP Nasdaq
- SNY Nasdaq
- Market Cap
- COP 110.7B
- SNY 123.6B
- IPO Year
- COP N/A
- SNY N/A
- Fundamental
- Price
- COP $88.58
- SNY $49.90
- Analyst Decision
- COP Buy
- SNY Buy
- Analyst Count
- COP 17
- SNY 2
- Target Price
- COP $123.94
- SNY $62.50
- AVG Volume (30 Days)
- COP 7.3M
- SNY 3.1M
- Earning Date
- COP 05-08-2025
- SNY 04-24-2025
- Dividend Yield
- COP 3.52%
- SNY 3.21%
- EPS Growth
- COP N/A
- SNY 39.56
- EPS
- COP 7.91
- SNY 5.45
- Revenue
- COP $59,090,000,000.00
- SNY $48,817,552,946.00
- Revenue This Year
- COP $7.62
- SNY $5.35
- Revenue Next Year
- COP $2.90
- SNY $6.69
- P/E Ratio
- COP $11.19
- SNY $18.73
- Revenue Growth
- COP 4.00
- SNY N/A
- 52 Week Low
- COP $79.88
- SNY $45.80
- 52 Week High
- COP $124.23
- SNY $60.12
- Technical
- Relative Strength Index (RSI)
- COP 45.02
- SNY 37.47
- Support Level
- COP $86.88
- SNY $51.67
- Resistance Level
- COP $92.26
- SNY $55.73
- Average True Range (ATR)
- COP 2.37
- SNY 0.89
- MACD
- COP 0.14
- SNY -0.12
- Stochastic Oscillator
- COP 26.24
- SNY 0.34
About COP ConocoPhillips
ConocoPhillips is a US-based independent exploration and production firm. In 2023, it produced 1.2 million barrels per day of oil and natural gas liquids and 3.1 billion cubic feet per day of natural gas, primarily from Alaska and the Lower 48 in the United States and Norway in Europe and several countries in Asia-Pacific and the Middle East. Proven reserves at year-end 2023 were 6.8 billion barrels of oil equivalent.
About SNY Sanofi ADS
Sanofi develops and markets drugs with a concentration in vaccines, immunology, oncology, cardiovascular disease, diabetes, and over-the-counter treatments. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing about 30% of total sales, but profits are shared with Regeneron. Just over 40% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.